Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 392

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 392
---
 reasonably be expected to constitute or result, in a Material Adverse Effect with respect to such party; |

| • |     | notifying the other party of any action to which it is a party that, if adversely determined, could prevent or materially delay or impede such party’s ability to consummate the transactions contemplated by the Merger Agreement; |

| • |     | making all required filings under the HSR Act; |

| • |     | cooperating with respect to certain tax matters; |

| • |     | cooperating in the preparation of this proxy statement/prospectus; |

| • |     | the delivery by Semnur to Denali of financial statements and other financial information; |

| • |     | Denali taking certain actions so that amounts will be released from the Trust Account and so that the Trust Account will terminate thereafter, in each case, pursuant to the terms and subject to the terms and conditions of the Trust Agreement; |

| • |     | ensuring Denali remains listed as a public company on the applicable Stock Exchange and that the Denali Ordinary Shares and Warrants remain listed or quoted on the applicable Stock Exchange through the Closing and that Semnur use its reasonable best efforts to prepare and file an initial listing application with the applicable stock exchange in connection with the transactions contemplated by the Merger Agreement; |

225

| • |     | Denali filing the New Semnur Certificate of Designations with the Secretary of State of Delaware following the consummation of the Domestication; |

| • |     | Denali adopting a resolution consistent with the interpretive guidance of the SEC so that the acquisition of New Semnur Common Stock (including, in each case, securities deliverable upon exercise, vesting or settlement of any derivative securities) pursuant to the Merger Agreement (and the other agreements contemplated hereby), by any person owning securities of Semnur who is expected to become a director or officer (as defined under Rule 16a-1(f) under the Exchange Act) of Denali following the Closing shall be an exempt transaction for purposes of Section 16(b) of the Exchange Act pursuant to Rule 16b-3 thereunder; and |

| • |     | Denali taking all actions necessary to call and hold a meeting of its shareholders to approve and adopt the Merger Agreement and the Proposals. |

Closing Conditions The consummation of the Business Combination is conditioned upon the satisfaction or waiver by the applicable parties to the Merger Agreement of the conditions set forth below. Therefore,